1. Home
  2. FUNC vs SGMT Comparison

FUNC vs SGMT Comparison

Compare FUNC & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First United Corporation

FUNC

First United Corporation

N/A

Current Price

$38.62

Market Cap

247.8M

Sector

Finance

ML Signal

N/A

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.39

Market Cap

238.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUNC
SGMT
Founded
1900
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
247.8M
238.7M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
FUNC
SGMT
Price
$38.62
$6.39
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$29.75
AVG Volume (30 Days)
16.7K
500.1K
Earning Date
10-20-2025
11-13-2025
Dividend Yield
2.72%
N/A
EPS Growth
56.67
N/A
EPS
3.84
N/A
Revenue
$83,662,000.00
N/A
Revenue This Year
$16.22
N/A
Revenue Next Year
$7.42
N/A
P/E Ratio
$9.94
N/A
Revenue Growth
17.79
N/A
52 Week Low
$24.66
$1.73
52 Week High
$42.50
$11.41

Technical Indicators

Market Signals
Indicator
FUNC
SGMT
Relative Strength Index (RSI) 66.28 39.03
Support Level $37.74 $6.02
Resistance Level $38.69 $7.29
Average True Range (ATR) 0.73 0.55
MACD 0.26 -0.15
Stochastic Oscillator 95.72 14.85

Price Performance

Historical Comparison
FUNC
SGMT

About FUNC First United Corporation

First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: